Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Bristol-Myers Squibb
(NY:
BMY
)
54.20
+0.60 (+1.12%)
Streaming Delayed Price
Updated: 7:00 PM EDT, Oct 3, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
25,093
Open
54.20
Bid (Size)
53.47 (1)
Ask (Size)
53.68 (1)
Prev. Close
53.60
Today's Range
54.20 - 54.20
52wk Range
39.35 - 57.65
Shares Outstanding
2,222,113,553
Dividend Yield
4.21%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
U.S. Food and Drug Administration Approves Perioperative Treatment of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Single-Agent Opdivo for Resectable Non-Small Cell Lung Cancer (NSCLC)
October 03, 2024
From
Bristol Myers Squibb
Via
Business Wire
2 Passive-Income Stocks to Load Up On in October
October 03, 2024
These two dividend powerhouses are ideal choices for passive-income investors.
Via
The Motley Fool
Performance
YTD
+2.73%
+2.73%
1 Month
+7.28%
+7.28%
3 Month
+36.66%
+36.66%
6 Month
+5.45%
+5.45%
1 Year
-4.46%
-4.46%
More News
Read More
Bristol-Myers Squibb's Profits, Stock Price Kick Into High Gear
October 03, 2024
Via
Investor's Business Daily
This Is What Whales Are Betting On Bristol-Myers Squibb
October 01, 2024
Via
Benzinga
NYSE:BMY Shows Potential for a Breakout.
September 23, 2024
Via
Chartmill
IGM Biosciences' New Found Focus: Pivots From Cancer To Autoimmune Diseases, Names New CEO
October 01, 2024
Via
Benzinga
Why Prime Medicine Stock Soared Nearly 12% Higher on Monday
September 30, 2024
Via
The Motley Fool
Prime Medicine Inks Cell Therapy Pact With Bristol Myers Squibb Worth Over $3.5B, Streamlines Pipeline
September 30, 2024
Via
Benzinga
Prime Medicine Announces Strategic Research Collaboration and License Agreement with Bristol Myers Squibb to Develop and Commercialize Multiple Prime Edited Ex Vivo T-Cell Therapies
September 30, 2024
From
Prime Medicine, Inc.
Via
GlobeNewswire
3 Surprisingly Underrated Stocks to Buy Right Now
September 28, 2024
Via
The Motley Fool
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults
September 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
Absence of Black Box Warning For Bristol Myers' Schizophrenia Treatment Could Enhance Alzheimer's Psychosis Potential
September 27, 2024
Via
Benzinga
Exposures
Product Safety
Bristol Myers Squibb Presents New Data from Two Trials Demonstrating Sotyktu (deucravacitinib) Efficacy in both Moderate-to-Severe Scalp Psoriasis and in a Real-World Setting
September 27, 2024
From
Bristol Myers Squibb
Via
Business Wire
14 Stocks Gain Momentum As August Inflation Comes In Below Expectations
September 27, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb' Cobenfy As New Class Of Treatment In More Than 3 Decades
September 27, 2024
Via
Benzinga
Exposures
Product Safety
Why Establishment Labs Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
September 27, 2024
Via
Benzinga
Wall Street On Wait-And-Watch Mode Ahead Of Inflation Data, Bitcoin Holds Above 65.5K: Analyst Says Volatility Ahead Providing Better Entry Point Into Long-term Bull Market
September 27, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Bristol-Myers Squibb's Novel Schizophrenia Drug Wins FDA Approval; BMY Stock Signals Breakout
September 26, 2024
Via
Investor's Business Daily
Exposures
Product Safety
FDA Casts Doubt On Use Of Merck, Bristol Myers' PD-1 Cancer Drugs For Certain Type Of Gastric Cancer Patients
September 25, 2024
Via
Benzinga
Exposures
Product Safety
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
September 25, 2024
Via
Benzinga
Exposures
Product Safety
Analysts Think There's Still Time to Get in on Edgewise, Up 332%
September 25, 2024
Via
MarketBeat
10 Health Care Stocks With Whale Alerts In Today's Session
September 23, 2024
Via
Benzinga
Bristol-Myers Acquired Drug KarXT Poised For FDA Approval As First New Type Of Schizophrenia Treatment In 70 Years
September 20, 2024
Via
Benzinga
Exposures
Product Safety
Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip
September 19, 2024
Via
Investor's Business Daily
2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?
September 19, 2024
Via
Investor's Business Daily
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.